Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;61(3):187-97.
doi: 10.1007/s12026-014-8557-5.

Role of SIRT1 in autoimmune demyelination and neurodegeneration

Affiliations
Review

Role of SIRT1 in autoimmune demyelination and neurodegeneration

Alvaro Martin et al. Immunol Res. 2015 Mar.

Abstract

Multiple sclerosis (MS) is a demyelinating disease characterized by chronic inflammation of the central nervous system, in which many factors can act together to influence disease susceptibility and progression. SIRT1 is a member of the histone deacetylase class III family of proteins and is an NAD(+)-dependent histone and protein deacetylase. SIRT1 can induce chromatin silencing through the deacetylation of histones and plays an important role as a key regulator of a wide variety of cellular and physiological processes including DNA damage, cell survival, metabolism, aging, and neurodegeneration. It has gained a lot of attention recently because many studies in animal models of demyelinating and neurodegenerative diseases have shown that SIRT1 induction can ameliorate the course of the disease. SIRT1 expression was found to be decreased in the peripheral blood mononuclear cells of MS patients during relapses. SIRT1 represents a possible biomarker of relapses and a potential new target for therapeutic intervention in MS. Modulation of SIRT1 may be a valuable strategy for treating or preventing MS and neurodegenerative central nervous system disorders.

PubMed Disclaimer

References

    1. J Neuropathol Exp Neurol. 2009 Jan;68(1):48-58 - PubMed
    1. Clin Cancer Res. 2014 Apr 1;20(7):1741-6 - PubMed
    1. Mol Aspects Med. 2008 Jun;29(3):187-200 - PubMed
    1. Drug Discov Today. 2014 Jul;19(7):980-4 - PubMed
    1. Curr Neurovasc Res. 2011 Aug 1;8(3):220-35 - PubMed

Publication types

MeSH terms

LinkOut - more resources